elafibranor   Click here for help

GtoPdb Ligand ID: 11135

Synonyms: GFT-505 | GFT505 | Iqirvo®
Approved drug PDB Ligand
elafibranor is an approved drug (FDA (2024))
Compound class: Synthetic organic
Comment: Elafibranor (GFT-505) is a PPARα/δ agonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 88.9
Molecular weight 384.14
XLogP 4.97
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
Isomeric SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
InChI InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
InChI Key AFLFKFHDSCQHOL-IZZDOVSWSA-N
References
1. Blair HA. (2024)
Correction: Elafibranor: First Approval.
Drugs, 84 (9): 1165. [PMID:39240532]
2. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. (2013)
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
Diabetes Care, 36 (10): 2923-30. [PMID:23715754]
3. Cariou B, Zaïr Y, Staels B, Bruckert E. (2011)
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
Diabetes Care, 34 (9): 2008-14. [PMID:21816979]
4. Sahebkar A, Chew GT, Watts GF. (2014)
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Expert Opin Pharmacother, 15 (4): 493-503. [PMID:24428677]